Invokana 100 mg film-coated tablets

DRUG3 trials

Sponsors

Center For Outcomes Research And Clinical Epidemiology S.r.l., Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA, Humanitas Mirasole S.p.A.

Conditions

Myocardial InfarctionType 2 Diabetes MellitusType 2 diabetes mellitusdiabetes mellitus

Phase 3

Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus

Not yet recruitingCTIS2025-523375-29-00

Humanitas Mirasole S.p.A.diabetes mellitus, Myocardial Infarction

Target: 300Updated: 2026-02-06

Phase 4

Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.

CompletedCTIS2024-518915-20-00

Center For Outcomes Research And Clinical Epidemiology S.r.l.Type 2 diabetes mellitus

Start: 2022-02-16End: 2025-10-02Target: 1167Updated: 2025-09-30

Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes

Active, not recruitingCTIS2025-520686-46-00

Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVAType 2 Diabetes Mellitus

Start: 2025-05-15Target: 504Updated: 2025-09-15